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Elevated levels of matrix
metalloproteinases reflect severity and
extent of disease in tuberculosis-diabetes
co-morbidity and are predominantly
reversed following standard anti-
tuberculosis or metformin treatment
Nathella P. Kumar1* , Kadar Moideen1, Vijay Viswanathan2, Basavaradhya S. Shruthi2, Shanmugam Sivakumar3,
Pradeep A. Menon3, Hardy Kornfeld4 and Subash Babu1,5
Abstract
Background: Matrix metalloproteinases (MMPs) are considered to be key mediators of tuberculosis (TB) pathology
but their role in tuberculosis – diabetes comorbidity (TB-DM) is not well understood.
Methods: To study the association of MMP levels with severity and extent of disease as well as bacterial burden in
TB-DM, we examined the systemic levels of MMP-1, − 2, − 3, − 7, − 8, − 9, − 10, − 12 and − 13 in individuals with
TB-DM and compared them to those with TB alone (TB) or healthy controls (HC).
Results: Circulating levels of MMP-1, − 2, − 3, − 7, − 10 and − 12 were significantly higher in TB-DM compared to
both TB and HC and MMP -13 levels were higher in comparison to HC alone. To understand the effect of standard
anti-tuberculosis therapy (ATT) on these MMP levels in TB-DM, we measured the levels of MMPs at the end of
treatment (post-treatment). Our findings indicate that ATT is associated with a significant reduction in the levels of
MMP-1, − 2, − 3, − 8 and − 13 post-treatment. Moreover, the levels of MMP-1, − 2, − 3, − 9 and − 12 were
significantly higher in TB-DM individuals with cavitary disease and/or bilateral disease at baseline but not post-
treatment. Similarly, the levels of MMP -1, − 2, − 3 and − 8 exhibited a significant positive relationship with bacterial
burden and HbA1c levels at baseline but not post-treatment. Within the TB-DM group, those known to be diabetic
before incident TB (KDM) exhibited significantly higher levels of MMP-1, − 2, − 10 and − 12 at baseline and of
MMP-1 and -3 post-treatment compared to those newly diagnosed with DM (NDM). Finally, KDM individuals on
metformin treatment exhibited significantly lower levels of MMP-1, − 2, − 3, − 7, − 9 and − 12 at baseline and of
MMP-7 post-treatment.
Conclusions: Our data demonstrate that systemic MMP levels reflect baseline disease severity and extent in TB-DM,
differentiate KDM from NDM and are modulated by ATT and metformin therapy.
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Background
Matrix metalloproteinases cover a large family of extra-
cellular enzymes that share common structural features,
predominantly those regions implicated in proteolytic
activity [1]. Twenty-eight different vertebrate MMPs
have been cloned to date and additional members con-
tinue to be identified. MMPs play a substantial role in
diverse biological functions involving many characteris-
tics of the immune response [2, 3]. These MMPs can
also function on pro-inflammatory cytokines, chemo-
kines and other proteins to regulate various aspects of
inflammation and immunity [3].
Previous studies have demonstrated that MMP levels
are increased in human TB and correlate strongly with
clinical and radiological markers of lung tissue destruction
[4]. In spite of crucial role of MMPs in lung matrix de-
struction in human TB, the principal mechanisms result-
ing in tissue damage have not been defined. In addition,
we have shown that MMP-1, − 7 and − 8 plasma levels
were significantly elevated in children with pulmonary TB
[5]. We have also shown that MMP-1 is an important bio-
marker for the discrimination of TB-DM from TB [6].
The anti-diabetic drug metformin was previously de-
scribed to exert anti-mycobacterial activity in vitro
and in vivo and treatment with metformin has been
shown to reverse the heightened mortality linked with
TB-DM [7, 8]. However, a comprehensive examination of
the association of MMPs with TB-DM and their relation-
ship to disease pathology or bacterial burden has not been
carried out. Similarly, the relationship of MMPs with TB
individuals with KDM or NDM and among TB-KDM in-
dividuals with or without metformin use has never been
examined. Since TB-DM is characterized by increased im-
mune pathology compared to TB alone [6, 9], we postu-
lated that one potential mechanism could be a systemic
expansion in the levels of MMPs in TB-DM individuals.
To address these gaps in knowledge, we examined the
association of the systemic levels of MMP-1, − 2, − 3, − 7,
− 8, − 9, − 10, − 12 and − 13 in TB-DM individuals and
compared them with TB and HC individuals. We demon-
strate elevated levels of MMPs in association with
TB-DM. We also determine the association of MMPs with
the extent and severity of lung disease and with bacterial
burden at baseline, indicating that MMPs are a reflection
of immune pathology in TB-DM. In addition, we show
the reversability of these findings following ATT. Finally,
we also demonstrate increase in MMPs in KDM com-
pared to NDM individuals and decrease in MMPs in those
using metformin therapy.
Methods
Ethics statement
The Ethical committees of Prof. M. Viswanathan Diabetes
Research Center and National Institute for Research in
Tuberculosis have approved the study. Informed written
consent was obtained from all participants.
Study population
Plasma samples were collected from 64 individuals with
active pulmonary TB with diabetes mellitus (TB-DM) and
24 individuals with active pulmonary TB (TB) and 24
healthy control individuals, enrolled in Chennai, India.
Pulmonary TB was diagnosed based on smear and culture
positivity for Mycobacterium tuberculosis (M.tb). To de-
fine cavitary disease as well as unilateral versus bilateral
lung involvement, chest X-rays were done for all the en-
rolled TB patients. Smear grades were used to determine
bacterial burden and classified as 1+, 2+ and 3+. During
the time of recruitment, all active TB cases had no record
of prior TB disease or anti-TB treatment (ATT). Glycemic
status (DM or normoglycemia) was diagnosed on the basis
of oral glucose tolerance test and/or glycated hemoglobin
(HbA1c) levels (for known diabetics), according to the
WHO criteria. Amongst the 64 TB-DM individuals, 32
were known diabetics (KDM) and 32 were newly diag-
nosed diabetics (NDM). Amongst the KDM individuals,
16 were on metformin containing anti-diabetic medication
and 16 were not. Healthy control individuals were asymp-
tomatic, had normal chest x-rays and were non-diabetic.
All individuals were BCG vaccinated, HIV negative and
had normal body mass index. The study groups were simi-
lar with regard to age and gender and the baseline charac-
teristics of the study participants are shown in Table 1.
Standard ATT was administered to TB-DM individuals
using the directly observed treatment, short course
(DOTS) strategy. At 6 months following ATT initiation,
fresh plasma samples were obtained. All TB-DM individ-
uals were culture negative at the end of ATT.
Elisa
Circulating levels of MMP-1, MMP-2, MMP-3, MMP-7,
MMP-8, MMP-9, MMP-10, MMP-12 and MMP-13 were
determined using a multiplex enzyme-linked immuno-
sorbent assay system (Bio-Rad Laboratories, Inc) in
plasma samples. The lowest detection limits were as fol-
lows: MMP-1, 115.8 pg/mL; MMP-2, 809 pg/mL; MMP-3,
199.2 pg/mL; MMP-7, 27.7 pg/mL; MMP-8, 31.7 pg/mL;
MMP-9, 257.5 pg/mL; MMP-10, 78.4 pg/mL; MMP-12,
18.5 pg/mL; MMP-13, 32.9 pg/mL.
Statistical analysis
Geometric means (GM) were used for measurements of
central tendency. Statistically significant differences be-
tween three groups were examined using the
Kruskal-Wallis test with Dunn's post-hoc test. Statistically
significant differences between two groups were examined
using the Mann Whitney test with Holm’s correction for
multiple comparisons. Wilcoxon signed rank test was
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used to compare MMP concentrations before and after
ATT. Linear trend post-test was used to compare MMP
concentrations with smear grades (reflecting bacterial bur-
den) and Spearman rank correlation was used to compare
MMP concentrations with HbA1c levels. Analyses were
performed using GraphPad PRISM Version 6.01.
Results
Study population characteristics
The baseline characteristics comprising demographic
and biochemical features of the study population are
shown in Table 1. TB-DM individuals had significantly
increased levels of fasting and post-prandial glucose as
well as glycated haemoglobin compared TB and HC in-
dividuals. No significant differences were observed in
age, sex, smear or culture grades at baseline between the
TB-DM and TB groups (Table 1).
Heightened levels of circulating MMPs in TB-DM and
reversal following ATT
As MMPs are linked with inflammation and tissue dam-
age as well as matrix remodelling in TB, we wanted to
examine the systemic levels of circulating MMPs in
TB-DM, TB and HC individuals. To this end, we esti-
mated the plasma levels of MMP-1, − 2, − 3, − 7, − 8, − 9,
− 10, − 12 and − 13 by multi-plex ELISA in TB-DM (n =
64), TB (n = 24) and HC (n = 24) individuals (Fig. 1). As
shown in Fig. 1a, systemic levels of MMP-1, − 2, − 3, − 7,
− 10, − 12 and − 13 (Additional file 1: Table S1) were sig-
nificantly higher in TB-DM compared to TB and HC indi-
viduals at baseline. To study the effect of ATT on MMP
levels in TB-DM, we measured the levels of MMPs in
TB-DM before (pre-T) and at the end of ATT (post-T). As
shown in Fig. 1b, systemic levels of MMP-1, − 2, − 3, − 8
and − 13 (Additional file 2: Table S2) were significantly di-
minished in TB-DM at 6 months post-T in comparison to
pre-T levels. Thus, TB-DM is associated with heightened
systemic levels of circulating MMPs at baseline and rever-
sal following standard ATT.
Circulating MMPs are markers of disease severity and
extent in TB-DM
To elucidate the association between the systemic levels of
circulating MMPs and disease severity in TB-DM, we mea-
sured the plasma levels of MMPs in TB-DM individuals
with cavitary versus non-cavitary disease. As shown in Fig. 2,
the circulating levels of MMP-1, − 2, − 3 and − 12 (Add-
itional file 3: Table S3) were increased in TB-DM individuals
with cavitary disease compared to those without. However,
upon completion of ATT and the consequent healing of
cavitary lesions, the circulating MMP levels exhibited no
significant difference between the individuals who presented
initially with cavity compared to those did not.
To elucidate the association between the systemic levels
of circulating MMPs and the radiographic extent of disease
in TB-DM, we measured the plasma levels of MMPs in
TB-DM individuals with bilateral versus unilateral disease
at baseline and post-treatment. As shown in Fig. 3, the cir-
culating levels of MMP-1, − 2, − 3, − 9 and − 12 (Additional
file 3: Table S3) were significantly increased in TB-DM in-
dividuals with bilateral disease compared to those with uni-
lateral disease. However, upon completion of ATT and the
consequent healing, the circulating MMP levels exhibited
no significant difference between the individuals who pre-
sented initially with bilateral disease compared to those did
not. Thus, disease severity and extent in TB-DM is linked
with increased systemic levels of circulating MMPs at base-
line but not after completion of TB treatment.
Correlation of circulating MMPs with estimated bacterial
burden
To elucidate the association of circulating MMPs and bac-
terial burden, we done a correlation of the circulating
levels of MMPs in TB-DM individuals with smear grades.
Table 1 Demographics of the study groups and biochemical parameters in TB-DM TB and HC
Study Demographics TB-DM TB HC p Value
No. of subjects recruited 64 24 24 –No significance
Gender (Male / Female) 44/20 17/7 14/10 –No significance
Median Age (Range) 52 (31–70) 43 (30–67) 35(27–62) –No significance
Median Height, cm 159 (129–176) 164 (121–181) 162 (125–190) –No significance
Median Weight, kg 49 (31–64) 44 (30–90) 55 (45–90) –No significance
Body mass index kg/m2 19.3 (13.2–32.6) 17.2 (12.2–21.2) 22.3 (18.2–24.7) –No significance
Smear Grade: 0/1+/2+/3+ 0/22/24/18 0/9/9/6 NA –No significance
Fasting Blood Glucose, mg/dL 158 (109–427) 93 (73–103) 88 (75–105) p < 0.0001
Post Prandial Glucose, mg/dL 220 (183–448) 112 (80–129) 110 (78–120) p < 0.0001
Glycated hemoglobin level, % 10.3 (7.3–15.6) 5.6 (5.0–5.8) 5.5 (5.0–5.7) p < 0.0001
The values represent the geometric mean (and the 95% confidence intervals) except for age where the median (and the range) are depicted. P values were
calculated using the Kruskal-Wallis test with Dunn’s post-hoc for multiple comparisons
P values captured in bold are statistically significant
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As shown in Fig. 4, MMP-1, − 2, − 3 and − 8 displayed a
significant positive correlation with smear grades in
TB-DM individuals, showing a positive association of
these factors with bacterial burden. However, upon com-
pletion of ATT the circulating MMP levels revealed no
significant correlation in TB-DM individuals with smear
grades. Thus, bacterial burden in TB-DM are linked with
heightened systemic levels of circulating MMPs at baseline
but not after successful completion of TB treatment.
Circulating MMPs exhibit a positive relationship with
HbA1c in TB-DM
To elucidate the association between systemic levels of
circulating MMPs and glycemic control in TB-DM, we de-
termined the relationship between the circulating levels of
MMPs in TB-DM with HbA1c levels (Fig. 5). As shown,
the systemic levels of MMP-1 exhibited a significant posi-
tive relationship, wear as MMP-7 and MMP-10 displayed
a borderline positive correlation with HbA1c levels in
TB-DM at baseline, showing a significant association of
these factors with poor glycemic control. Similarly, only
the systemic levels of MMP-10 exhibited a significant
positive relationship with HbA1c levels at post-treatment,
indicating a significant reversal of the association of
MMPs with poor glycemic control at the end of ATT.
Known DM is associated with increased circulating levels
of MMPs during pre and post treatment conditions
To determine whether MMP levels differ between
known diabetic individuals (KDM) and newly diagnosed
a
b
Fig. 1 Elevated circulating levels of MMPs in TB-DM individuals. (a) The plasma levels of MMPs were measured in TB-DM (n = 64), TB (n = 24) and
HC (n = 24) individuals at baseline. The data are represented as scatter plots with each circle representing a single individual. P values were
calculated using the Kruskal-Wallis test with Dunn’s post-hoc for multiple comparisons (b) The plasma levels of MMPs were measured in TB-DM
individuals at baseline (pre-T) and at 6 months of ATT (post-T). The data are presented as line graphs with each line representing a single
individual. P values were calculated using the Wilcoxon signed rank test
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diabetes (NDM) in TB-DM individuals, we measured
the circulating levels of MMPs in KDM (n = 32) and
NDM (n = 32) individuals (Fig. 6). As shown in Fig. 6a,
systemic levels of MMP-1, − 2, − 10 and − 12 (Add-
itional file 4: Table S4) were significantly higher in KDM
compared to NDM individuals at baseline. As shown in
Fig. 6b, systemic levels of MMP-1 and MMP-3 (Add-
itional file 4: Table S4) were significantly higher in KDM
compared to NDM individuals upon completion of
ATT. Thus, KDM is associated with elevated systemic
levels of circulating MMPs at baseline as well as follow-
ing standard ATT.
Metformin treatment associated with diminished
circulating MMPs
Since the anti-diabetic drug metformin is associated with
protection against mortality in TB-DM, we wanted to
examine the systemic levels of circulating MMPs in
KDM individuals on metformin treatment (n = 16) com-
pared to those on non-metformin regimens (n = 16). No
significant differences were observed in HbA1c levels be-
tween KDM individuals on metformin compared to
KDM individuals not on metformin. As shown in Fig. 7a,
systemic levels of MMP-1, − 2, − 3, − 7, − 9 and − 12
(Additional file 5: Table S5) were significantly
Fig. 2 Elevated circulating levels of MMPs in cavitary disease in TB-DM individuals. The plasma levels of MMPs were measured in TB-DM
individuals with cavitary versus non-cavitary disease at baseline. The data are represented as scatter plots with each circle representing a single
individual. P values were calculated using the Mann-Whitney test with Holm’s correction for multiple comparisons
Fig. 3 Elevated circulating levels of MMPs in bilateral disease in TB-DM individuals. The plasma levels of MMPs were measured in TB-DM
individuals with bilateral versus unilateral disease at baseline. The data are represented as scatter plots with each circle representing a single
individual. P values were calculated using the Mann-Whitney test with Holm’s correction for multiple comparisons
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diminished in KDM individuals on metformin com-
pared to KDM individuals not on metformin. As
shown in Fig. 7B, MMP-7 (Additional file 5: Table S5)
alone was significantly diminished in KDM individuals on
metformin compared to KDM individuals not on metfor-
min upon completion of ATT. Thus, metformin therapy
in KDM individuals is associated with diminished systemic
levels of circulating MMPs.
Discussion
The increased severity of TB disease in the face of DM
comorbidity has a major negative impression on public
Fig. 4 Circulating MMPs are marker of bacterial burden in TB-DM. The relationship between the plasma levels of MMPs and smear grades as
estimated by sputum smears was examined in TB-DM individuals at baseline. The data are represented as scatter plots with each circle
representing a single individual. P values were calculated using the Linear trend post – test
Fig. 5 Significant correlation between circulating levels of MMPs and glycemic parameters in all TB-DM individuals. The relationship between the
plasma levels of MMPs and HbA1c levels was examined in all PTB individuals with and without DM at baseline. The data are represented as
scatter plots with each circle representing a single individual. P values were calculated using the Spearman Rank Correlation
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health, specifically in the countries where both diseases
are vastly endemic. There is also strong confirmation that
DM contributes significantly to TB incidence, which in is
turn linked with poor TB treatment outcomes [10, 11].
The immunological basis for enhanced susceptibility in
TB-DM comorbidity is relatively unknown, although re-
cently published data advocates that innate and adaptive
immune responses might be affected [11–13]. MMPs are
a family of zinc-dependent proteases consisting of two
conserved domains, a prodomain and a catalytic domain
[14]. Collectively MMPs can successfully degrade all ele-
ments of the extracellular matrix, including collagens,
laminin, fibrillar, vitronectin, and proteoglycans [14]. After
M.tb infection, the local cellular and adjacent tissues are
remodelled to accelerate leukocyte infiltration and the ini-
tiation of granuloma formation and previously published
cellular and animal studies report that MMPs play an
important role in the cellular recruitment, tissue remodel-
ling, and destruction [15]. MMP activity has been involved
in driving TB pathology, and it has critical immunological
and pathological roles. Although MMPs have been
reviewed broadly in other destructive pulmonary patholo-
gies [16], their role in TB disease and pathogenesis is still
being explored.
Multiple MMPs are up-regulated in human TB and it
has been shown that plasma concentrations of MMP-1,
− 7 and − 8 were increased in TB patients compared to
controls [17–19]. Similarly, MMP-1, − 2, − 3, − 8 and − 9
are elevated in sputum samples of TB patients compared
to healthy volunteers [20]. Published studies from
TB-HIV coinfection reported that in sputum, multiple
MMPs are elevated in TB patients compared to controls.
However authors reported that TB (HIV+) displayed
lower median sputum MMP-1, − 2, − 3, and − 9
a
b
Fig. 6 Elevated circulating levels of MMPs in KDM individuals. (a) The plasma levels of MMPs were measured in TB-DM individuals with known
diabetes. (KDM) versus newly diagnosed diabetes (NDM) at baseline. (b) The plasma levels of MMPs were measured in TB-DM individuals with
known diabetes (KDM) versus newly diagnosed diabetes (NDM) at 6 months of ATT. The data are represented as scatter plots with each circle
representing a single individual. P values were calculated using the Mann-Whitney test with Holm’s correction for multiple comparisons
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concentrations compared to TB (HIV−). Together, this
data supports a role for sputum MMPs involved in pul-
monary TB driven matrix degradation [21]. MMP-1, − 2,
− 8 and − 9 were found to be elevated in pleural fluid of
patients with TB compared to pleural fluid of non-TB
pleuritis [22–24]. MMP-9 concentrations are increased in
the cerebrospinal fluid of patients with TB meningitis [25]
and correlate with extent of neurological compromise
[26]. We previously reported that that MMP-1, − 7 and −
8 plasma levels were significantly elevated in children with
pulmonary TB compared to healthy controls [5].
In agreement with previous reports that systemic
levels of MMPs increase significantly with the severity of
TB disease and that clinical severity of TB is increased
by comorbid DM, our current study revealed that
TB-DM individuals exhibit significantly higher systemic
levels of MMP-1, − 2, − 3, − 7, − 10, − 12 and − 13 com-
pared to TB and healthy individuals. Our data also re-
vealed a significant association of MMP levels with the
severity of TB disease (as estimated by the bilateral and
cavitary disease) and increasing bacterial burden only at
baseline, indicating that comorbid DM amplifies this re-
sponse, which might mirror increased bacterial load
and/or a specific perturbation of immune function.
Thus, MMPs appear to be linked with pathology and
bacterial burden in TB-DM. Of additional interest are
the findings that MMP levels are positively correlated
with HbA1c, indicating an association with poor gly-
cemic control which drives diabetic complications in all
tissues. [27, 28]. The published data reports that elevated
MMP-8 and -9 levels were directly connected with neu-
trophil markers, with MMP-8 expressing neutrophils
a
b
Fig. 7 Diminished circulating levels of MMPs in KDM individuals on metformin treatment. (a) MMPs were measured in KDM individuals on metformin
treatment versus no metformin treatment at baseline. (b) The plasma levels of MMPs were measured in KDM individuals on metformin treatment
versus no metformin treatment at 6 months of ATT. The data are represented as scatter plots with each circle representing a single individual. P values
were calculated using the Mann-Whitney test with Holm’s correction for multiple comparisons
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placed in the wall of TB cavities, which in turn imply a
role of neutrophils in driving tissue destruction and cavi-
tation in TB [4]. Similarly, TB patients with extensive tis-
sue destructive disease on the chest X-ray were shown
to have augmented sputum MMP-1 levels compared
with those with less tissue damage [29]. The heightened
levels of multiple MMPs suggest that a number of prote-
ases may be a factor for tissue destruction and cavitation
in TB, but their relative significance is presently un-
known. Our results, therefore, imply that MMP inhib-
ition might be uniquely useful in host directed therapy
(HDT) in TB-DM patients.
After completion of anti TB treatment, matrix-degrading
phenotype solves quickly in patients with fully
drug-sensitive pulmonary TB and the levels of MMP-1, − 3
and − 8 concentrations in sputum decline markedly in the
first 2 weeks of anti-TB treatment [20]. Consistent with that
observation, we observed a significant reversal of MMP
levels in most TB-DM patients at the completion of TB
treatment. With radiographic and microbiological im-
provement, MMP levels fall in most TB-DM patients
and become indistinguishable from TB alone. Thus,
the pattern of MMP elevation and correlation with
radiographic features and sputum status suggest that
DM is associated with increased TB disease severity
that might be mediated in part by MMP activities,
and this condition is treatment-responsive. While a
few previous reports have described post-treatment
effects on MMPs, this study is the first to our know-
ledge to extensively characterize the effect of ATT on
MMP levels in TB disease.
A previous study from our group reported that there
was a bimodal distribution of baseline HbA1c between
KDM and NDM individuals in the EDOTS study cohort,
with significantly higher baseline A1c in the KDM group
[30]. Our current study adds to this apparent heterogen-
eity in the presentation of TB-DM comorbidity. We
found that circulating MMPs were significantly en-
hanced in KDM compared to NDM groups at baseline
and after completion anti-TB treatment, reflecting the
increased severity of TB disease in KDM individuals.
The most frequently-prescribed anti-diabetic agent met-
formin has drawn attention as a potential adjunctive,
host-directed therapy (HDT) for TB independent of its
glucose-lowering activity [7, 31, 32]. Studies from mur-
ine models reported that metformin treatment was
found to reduce M.tb growth and improve lung path-
ology. The use of metformin-containing DM treatment
regimens also is associated with reduced risk for TB pro-
gression and decreased mortality and lung cavitation in
active TB patients [7, 8]. Our findings provide new evi-
dence for a host – directed role for metformin in that
individuals on metformin treatment exhibited dimin-
ished systemic MMP levels, suggesting a host –
protective effect of metformin in TB-DM with possible
implications for its use in TB without DM.
Conclusion
Our data on MMPs overall suggest that upregulation of
MMPs is a typical characteristic of TB-DM
co-morbidity. Our data also add to the growing list of
evidence indicating heightened immune activation in
this immune-metabolic nexus. MMPs appear to act as
reliable and reproducible biomarkers for therapeutic
monitoring of TB-DM disease. Finally, our study rein-
forces the necessity of aggressively controlling the dys-
regulated glucose metabolism and inflammatory milieu
that characterized TB-DM to minimize inflammatory
pathology and possibly poor outcomes in TB-DM
co-morbidity. Therefore, our findings demonstrate that
systemic MMP levels reflect baseline disease severity
and extent in TB-DM, differentiate KDM from NDM,
and are modulated by ATT and metformin therapy.
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